Goal of the analysis:
Assess a medical device company’s processes for monitoring and reporting device performance, safety, and quality after market release. Confirm compliance with regulatory requirements (for example, FDA’s 21 CFR Part 803, EU MDR Article 83-90) and ensure that adverse events, complaints, and other feedback are effectively captured and addressed.
Data required:
- Post-market surveillance (PMS) plans and procedures
- Adverse event reporting records and vigilance submissions
- Complaint handling procedures and records
- Data on device-related incidents or failures, including corrective actions taken
- Trends analysis of returned product data
- Post-market clinical follow-up (PMCF) or post-market performance follow-up (PMPF) studies, if applicable
- Regulatory authority correspondence or audit findings related to PMS and vigilance
Detailed step-by-step instruction on how to conduct the analysis:
- Identify applicable PMS and vigilance regulations. Determine the relevant reporting requirements for each market (for example, FDA, EU MDR, Health Canada, etc.) and review corresponding guidance.
- Examine the company’s PMS plan and procedures. Check if the plan outlines data collection methods, frequency of analysis, responsibilities, and actions for identified risks or trends.
- Review complaint handling processes. Evaluate how complaints are logged, investigated, documented, and resolved. Verify that root causes are identified and corrective/preventive actions (CAPAs) are tracked.
- Assess vigilance and adverse event reporting. Confirm that adverse events are reported to regulators within required timelines and that serious incidents are handled per local regulations.
- Analyze trending and signal detection methods. Check if the company uses statistical or other tools to identify significant increases in complaints, failures, or adverse events.
- Evaluate post-market clinical or performance follow-up activities. Determine whether the company collects real-world evidence to confirm ongoing safety and effectiveness, especially for higher-risk devices.
- Check documentation and record-keeping. Ensure traceability and completeness of all PMS- and vigilance-related records, including audits and management review minutes.
- Summarize findings and recommend improvements. Highlight areas where the PMS system meets or exceeds regulatory expectations and pinpoint gaps that may require enhancements.
Format of the output of analysis:
- A written report describing current PMS and vigilance processes, highlighting compliance strengths and weaknesses
- A gap analysis table mapping actual practices to regulatory requirements (for example, reporting timelines, investigation procedures)
- A risk-based action plan for improving post-market activities, with assigned owners and deadlines
- An executive summary noting key findings, overall compliance status, and recommended improvements
How to interpret results:
- Effective PMS and vigilance systems show timely detection, investigation, and reporting of issues, alongside clear documentation of corrective actions.
- Delays in reporting adverse events, incomplete complaint records, or recurring device failures may indicate systemic process weaknesses or potential regulatory noncompliance.
- Ongoing post-market clinical or performance follow-up can demonstrate proactive efforts to validate continued device safety and efficacy.
Steps a company can take to improve on this measure:
- Implement automated tools and standardized forms for complaint handling and adverse event tracking.
- Train employees and distributors on identifying, recording, and escalating post-market issues.
- Perform regular reviews of PMS data, using trend analysis to detect emerging risks early.
- Strengthen documentation practices and maintain a thorough audit trail for all vigilance activities.
- Engage with regulatory bodies or external experts to clarify evolving post-market requirements and incorporate best practices.
